Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK science & innovation head resigns:

This article was originally published in Clinica

Executive Summary

On the eve of a UK review of science and innovation policy, Lord Sainsbury of Turville has resigned as the minister responsible for this area. The timing of the move, ostensibly to dedicate himself to his business and charitable activities, has been met with much speculation in commercial and parliamentary circles. Dr Simon Best, chairman of the BioIndustry Association (BIA), appraised his tenure as "integral to the much-improved position of science and bioscience in this country", while noting his contribution to the science and innovation strategy review. He will continue to advise the government on a part-time basis on how UK companies can better harness innovation, Clinica understands. Malcolm Wicks (formerly energy) becomes responsible for science, which has a budget of £3.4bn ($6.5bn).

You may also be interested in...



COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel